|
By Susan Najjar RNA therapies have surged into the spotlight in recent years, thanks to their role in the rapid development of COVID-19 vaccines. But according to Nigel Theobald, CEO of N4 Pharma, the real story is only just beginning. In a recent interview with Life Sciences Decoded, Nigel broke down the fundamentals of RNA therapeutics and explained why the next major leap in this field depends not on the RNA itself—but on how it's delivered. What Are RNA Therapeutics, and Why Do They Matter? Nigel offers a down-to-earth explanation: “RNA, along with DNA, are nucleic acids—core components of all human life. RNA acts as a messenger, translating DNA's genetic instructions into proteins that the body needs to function.” But in diseases like cancer, inflammatory bowel disease (IBD), or viral infections, the body may produce too much or too little of a critical protein. RNA therapies aim to correct that imbalance. They either:
The potential? Tremendous. RNA can target previously "undruggable" diseases, offers a faster path to discovery than traditional small molecules or antibodies, and can even be tailored for personalized medicine. The Catch: Delivery is Everything Despite the promise, one glaring challenge remains: getting RNA into the right cells safely and effectively. “RNA is fragile,” Nigel explains. “The body immediately tries to break it down. Even if you protect it, you still face barriers like the cell membrane. Both RNA and the cell surface carry negative charges—they repel each other. Most delivery systems only succeed by overwhelming the body with a large dose, hoping a small fraction gets through.” And even if RNA enters a cell, it can get stuck in the endosome and never reach the cytoplasm where it’s needed. Add to that the fact that today’s systems tend to deliver RNA indiscriminately across the body—most ending up in the liver—and you have a delivery bottleneck limiting the potential of RNA therapies. Enter Nuvec®: A Novel Silica-Based Delivery System To solve this, N4 Pharma developed Nuvec®, a silica nanoparticle with a unique “spiky” structure that mimics grass burrs sticking to your socks. This structure:
“Existing systems like lipids or viral vectors can only deliver one thing at a time, and they’re expensive and complex to make,” Nigel explains. “Our silica particles are easy to manufacture, scalable, and low-cost. We’re not just solving delivery—we’re expanding what delivery can do.” From Science to Application: A New Hope for IBD N4 Pharma’s first clinical candidate--N4-101—is being developed for ulcerative colitis, a serious form of inflammatory bowel disease. What makes it stand out?
In preclinical studies, N4-101 demonstrated:
All with a capsule designed to release at the ideal pH level—directly in the upper GI tract.  A Future Beyond Injections
So, are injections the only route for RNA therapies? “Not anymore,” Nigel says. “They only dominate because of today’s limitations. But with novel delivery systems like Nuvec, we’re proving that oral and even topical applications are possible.” And that opens the door to a future where RNA therapies could be taken as easily as antibiotics—targeting everything from rare genetic diseases to common chronic conditions. The Bottom Line: RNA Therapies Need Better Delivery to Realize Their Promise The science behind RNA is sound. The potential is vast. But as Nigel puts it, “RNA therapeutics are only as effective as the systems that deliver them.” N4 Pharma’s Nuvec system is tackling this head-on—with a delivery platform that is protective, scalable, customizable, and most importantly, patient-friendly. As the industry shifts from promise to practical application, innovations in delivery may well be the key that unlocks RNA’s full therapeutic power.
0 Comments
By Susan Najjar
In our previous post, we examined why thought leadership matters in life sciences: it builds trust, attracts top talent, drives engagement, and translates complex science into actionable insight. Now comes the practical question: How do you establish yourself as a credible thought leader in a field defined by complexity, regulation, and rapid innovation? Here’s a strategic framework. 1. Narrow Your Focus to Increase Your Impact Effective thought leaders don’t try to cover every development across the sector. They specialize in high-impact areas where their expertise can drive real dialogue and change. Focus your lens:
Ask yourself: What questions aren't being addressed in my field? What assumptions need challenging? Great thought leadership often starts by addressing the blind spots. 2. Share Ideas at the Speed of Innovation Publishing in peer-reviewed journals is essential, but it’s not enough. Thought leaders today engage dynamically across platforms that move faster than traditional academic channels. Consider:
3. Lead with Framing, Not Just Facts You’re not just explaining mRNA stability. You’re articulating why it matters for global vaccine equity, biomanufacturing, or regulatory policy. Thought leadership positions the why now, not just the what is. Strong framing examples:
4. Make the Technical Tangible Even among experts, clarity accelerates trust. Make scientific insights easier to contextualize by linking them to outcomes:
5. Build Dialogue, Not a Monologue Thought leadership is relational. It involves amplifying others, not just broadcasting your own message.
6. Identify Gaps—Then Lead Into Them The most compelling thought leadership often emerges where others hesitate:
7. Prioritize Substance Over Visibility True thought leadership is not self-promotion. It’s about elevating your field. That means:
It’s less about being seen everywhere and more about showing up where it counts, with perspective that matters Final Takeaway: Teach, Challenge, and Connect You’re not just advancing your company or your research, you’re shaping how your field thinks. And in life sciences, that influence carries real-world impact.
By Susan Najjar
The term thought leadership is often met with skepticism in life sciences. It's used so frequently that many professionals dismiss it altogether. But when applied with substance, thought leadership becomes a valuable tool, one that helps organizations articulate their vision, build credibility, and influence the broader scientific conversation. In a highly technical and risk-aware industry, how you communicate can matter as much as what you’re building. Companies that lead the conversation gain visibility, trust, and traction. Those that stay silent risk being overlooked. 1. Science No Longer Sells Itself A breakthrough discovery isn’t enough on its own. You might have identified a new biomarker or developed a novel AI model, but without a clear and compelling story, it may not get noticed. 2. Influence Builds Trust Life sciences is a sector defined by smart skepticism. Partners, buyers, clinicians, and investors are cautious by design. They evaluate not just the strength of your vision and pipeline, but also the depth of your understanding and your ability to communicate with clarity. 3. Thought Leaders Set the Narrative Innovation is constant in life sciences. From gene editing to microbiome research, the pace is staggering. In these rapidly evolving areas, the most influential voices are often those who can distill complexity and shape discussion. Effective thought leadership allows you to guide how your field is understood. You become the reference point. Your perspectives, frameworks, and questions set the tone for others. 4. It Attracts the Right Talent People want to work for companies that stand for something. Skilled scientists, engineers, and professionals seek environments that offer more than tasks. They want purpose, clarity, and leadership. When your leadership team publishes meaningful insights or shares perspectives on industry challenges, you signal that your organization is thoughtful, forward-looking, and worth joining. For high-performing candidates, this matters. 5. It Scales and Delivers Lasting Value Unlike drug development or clinical trials, thought leadership doesn't require regulatory review or years of lead time. It scales easily across blogs, webinars, LinkedIn posts, podcasts, newsletters, and media interviews. Done well, it builds brand equity, credibility, and engagement. It’s one of the few strategic tools with immediate visibility and long-term value. 6. Video Accelerates Visibility and Trust Thought leadership is most effective when it’s seen and heard, not just read. In a digital-first ecosystem, video has become the most powerful way to communicate expertise at scale. Scientific leaders who appear in interviews, panel discussions, or short-form videos build a stronger, faster connection with their audience. How to Communicate with Clarity Life sciences content can easily become dense and technical. To stand out:
Final Thoughts In an industry where nearly everyone claims to be “first” or “next-generation,” how you talk about your work can differentiate you as much as the work itself. Thought leadership is not a trend. It is a strategic tool. It turns science into story, knowledge into influence, and perspective into partnerships. And today, the most effective thought leaders aren't just publishing articles, they’re showing up on screen. That’s where visibility starts, and where real impact begins. This article reviews how thought leadership builds trust, drives engagement, attracts talent, and turns your science into story. Stay tuned for our next blog that discusses practical steps you can take to standout as thought leader in life sciences. In biopharma, time isn’t just money, it’s product, safety, and reputation on the line. Yet for decades, manufacturers have been operating in the dark, waiting five to twenty-eight days for microbial test results that determine whether a batch is safe or contaminated. That delay can cost companies tens to hundreds of millions of dollars per incident. On a recent episode of Life Sciences Decoded, I sat down with Dr. Jack Regan, CEO, CTO, and Co-Founder of MantaBio, to discuss how his company is tackling this massive bottleneck with automation, PCR-based detection, and real-world insights. The Cost of Flying Blind In the biopharma world, manufacturing happens in warm, nutrient-rich bioreactors which are perfect not just for growing therapeutic biologics like Keytruda or Humira, but also for harboring microbial contamination. “If you're waiting 28 days to detect contamination, you're flying blind,” Regan explained. “You could be losing a $20 million batch or worse, contaminating multiple lines from a single source.” Contamination risks extend beyond product loss. A single event can lead to:
MantaBio’s 2-Hour Solution Enter MantaBio, a company designing a fully automated, PCR-based microbial detection system called MantaVision, purpose-built for the demands of biomanufacturing. “We’re not adapting clinical tech into biopharma,” Regan noted. “We’re building this from the ground up for industrial-scale testing.” Unlike traditional methods based on century-old cell culture, which involve plating samples and waiting for colonies to grow, MantaBio delivers results in just two hours. That speed allows manufacturers to detect contamination early, intervene faster, and avoid unnecessary product loss.  Designed for Manufacturing Environments
A major advantage of MantaBio’s approach? It eliminates one of the biggest risks in microbial detection: sub-sampling errors. Traditional methods often rely on testing small sample volumes, which can easily miss low-level contamination. MantaVision is engineered to process larger volumes, increasing the statistical likelihood of catching contaminants before they become costly. And it’s not just about volume, it’s also about usability. The system is:
As Jack Regan puts it: “It’s like the Keurig of molecular biology. Pop in your sample, and out comes a genetic result you can trust.” A Heart Monitor for Your Bioreactor What makes MantaVision more than just a faster test is how it integrates across the entire manufacturing process. The MantaVision is intentionally modular by design, so that customers can easily scale up to meet their testing needs. Most companies would like to deploy 4-5 systems per line, testing at multiple stages, fermentation, harvest, purification, and final product. It’s like having a continuous heart monitor for the bioreactor. “If something spikes, you know early,” Regan explained. “You can pause, isolate, and resolve the issue before it snowballs.” That kind of real-time insight doesn’t just save product. It gives manufacturers a clear path to more reliable operations, fewer recalls, and shorter time to market. Not Just Faster — Smarter Beyond rapid detection, MantaBio’s platform also supports speciation which is the ability to identify which microbe is present, not just whether contamination occurred. That insight helps teams perform root-cause analysis and prevent recurrence. “The goal isn’t just speed,” Regan said. “It’s confidence in the results, in the product, and in the decisions you make next.” What’s Next for MantaBio? While the system is still in development, MantaBio is already working closely with leading biomanufacturers to ensure the platform meets real-world needs. The team is conducting rigorous validation, refining usability, and aligning with evolving regulatory expectations. “There’s currently no dominant player delivering this kind of molecular testing in biopharma,” Regan said. “We’re building the system the industry has been asking for.” And that could change everything. Want to learn more? Visit mantabio.com or follow MantaBio on LinkedIn for updates. Listen to the full conversation on Life Sciences Decoded |
Authors
Meghan O'Sullivan
Susan Najjar
|